Cancer Research

The current landscape of regenerative medicine has reached a historic turning point where biological breakthroughs in gene editing no longer serve as the primary limiting factor for patient recovery. While the laboratory science behind cell and gene therapies has matured with breathtaking speed,

The recent failure of the high-profile Phase 3 LAGOON trial involving Zepzelca has sent shockwaves through the oncology community, raising urgent questions about the reliability of surrogate endpoints in modern drug regulation. While the drug initially received accelerated approval based on a

The historical paradigm where Western laboratories exclusively dictated the rhythm of pharmaceutical progress is rapidly disintegrating as China establishes itself as a primary source of high-value drug candidates. For many decades, the global healthcare sector followed a remarkably predictable

The emergence of chimeric antigen receptor T-cell therapy has revolutionized the oncological landscape by providing a potent "living drug" that can hunt and destroy malignant cells, yet nearly half of all patients still experience clinical relapses that threaten the long-term viability of this

The global biopharmaceutical industry is currently undergoing a radical metamorphosis as legacy therapeutic models are replaced by living cell therapies that offer the potential to permanently correct underlying genetic and immunological pathologies. Japan has emerged as the definitive epicenter of

The shift toward perceiving oncological pathologies as dynamic ecological systems has fundamentally altered the trajectory of modern clinical intervention and therapeutic research. Recent breakthroughs led by specialized teams at Peking University have moved the medical community away from the